The FDA accepted a supplemental application for Breyanzi to treat adults with relapsed or refractory marginal zone lymphoma ...

Quarterly revenue from Yescarta came in at $393 million, which was a 5% decline from the second quarter of last year, while ...

The supplemental New Drug Application is supported by data from the Phase II TRANSCEND FL trial (NCT04245839), which showed ...

Bristol Myers Squibb today announced the Phase 2 TRANSCEND FL trial evaluating Breyanzi ® in adult patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma met its primary ...

Bristol-Myers Squibb sees stabilizing sales, growth in key drugs, and raised guidance. Click to read more about why BMY is an ...

Bristol Myers Squibb today announced the U.S. Food and Drug Administration has granted accelerated approval of Breyanzi ®, a CD19-directed chimeric antigen receptor T cell therapy, for the ...

Breyanzi ® offers diffuse large B-cell lymphoma patients facing relapse or refractory disease earlier access with more personalized second-line treatment options. In the pivotal Phase 3 TRANSFORM ...

When your BREYANZI is ready, your healthcare provider will give it to you through a catheter placed into your vein (intravenous infusion). BREYANZI is given as infusions of 2 different cell types.

B-cell aplasia and hypogammaglobulinemia can occur in patients receiving BREYANZI. In clinical trials of BREYANZI, hypogammaglobulinemia was reported as an adverse reaction in 10% of patients.

BREYANZI can increase the risk of life-threatening infections that may lead to death. Tell your healthcare provider right away if you develop fever, chills, or any signs or symptoms of an infection.

BREYANZI can lower one or more types of your blood cells (red blood cells, white blood cells, or platelets). After treatment, your healthcare provider will test your blood to check for this.